ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Moderate Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $77.33.

Several equities analysts have recently commented on the company. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 33,981 shares of company stock valued at $1,970,066 in the last ninety days. 12.70% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. Innealta Capital LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the second quarter valued at about $85,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $207,000. Finally, HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $222,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 3.6 %

ANIP stock opened at $57.23 on Monday. The business’s 50 day simple moving average is $58.22 and its 200 day simple moving average is $60.64. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The firm has a market capitalization of $1.20 billion, a PE ratio of -104.05 and a beta of 0.71. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the prior year, the firm earned $1.05 earnings per share. The company’s revenue was up 12.5% on a year-over-year basis. As a group, research analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.